Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 8, Issue 2
January 23 2024
Issue Cover

Table of Contents

INSIDE BLOOD ADVANCES

Checkpoints: roadblocks or repairs for the CAR-T journey?
Clinical Trials & Observations
Jennifer L. Crombie,Caron A. Jacobson
View Articletitled, Checkpoints: roadblocks or repairs for the CAR-T journey?
An immunocompetent model to uncover the secrets of bispecifics
Joseph E. Maakaron
View Articletitled, An immunocompetent model to uncover the secrets of bispecifics

REVIEW ARTICLE

Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies
Clémentine Baguet,Jérôme Larghero,Miryam Mebarki
View Articletitled, Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies

CLINICAL TRIALS AND OBSERVATIONS

Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial
Clinical Trials & Observations
Swaminathan P. Iyer,Patrick B. Johnston,Stefan K. Barta
View Articletitled, Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial
Supplemental data
Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
Clinical Trials & Observations
Kathelijn Fischer,Gili Kenet,Karin Kurnik,Manuel Carcao,Johannes Oldenburg,Torben Stamm-Mikkelsen,Ana Rosa Cid Haro,Minna Koskenvuo,Jan Blatny,Christoph Königs,on behalf of the PedNet Study Group
View Articletitled, Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
Supplemental data
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Clinical Trials & Observations
Andrew Spencer,Philippe Moreau,Maria-Victoria Mateos,Hartmut Goldschmidt,Kenshi Suzuki,Mark-David Levin,Pieter Sonneveld,Robert Z. Orlowski,Sung-Soo Yoon,Saad Z. Usmani,Katja Weisel,Donna Reece,Tahamtan Ahmadi,Huiling Pei,Wendy Garvin Mayo,Xue Gai,Jodi Carey,J. Blake Bartlett,Robin Carson,Meletios A. Dimopoulos
View Articletitled, Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Supplemental data
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Clinical Trials & Observations
Mats Jerkeman,Arne Kolstad,Martin Hutchings,Annika Pasanen,Leo Meriranta,Carsten Utoft Niemann,Rasmus Rask Kragh Jørgensen,Tarec Christoffer El-Galaly,Jon Riise,Sirpa Leppä,Jacob Haaber Christensen,Kristina Sonnevi,Lone Bredo Pedersen,Karin Fahl Wader,Ingrid Glimelius
View Articletitled, MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
Supplemental data
Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study
Clinical Trials & Observations
Peter Bader,Ulrike Pötschger,Jean-Hugues Dalle,Laura M. Moser,Adriana Balduzzi,Marc Ansari,Jochen Buechner,Tayfun Güngör,Marianne Ifversen,Gergely Krivan,Herbert Pichler,Marleen Renard,Raquel Staciuk,Petr Sedlacek,Jerry Stein,Jan Robert Heusel,Tony Truong,Jacek Wachowiak,Akif Yesilipek,Franco Locatelli,Christina Peters
View Articletitled, Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study
Supplemental data
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Clinical Trials & Observations
Sheng F. Cai,Ying Huang,Jennie R. Lance,Hsiaoyin Charlene Mao,Andrew J. Dunbar,Samantha N. McNulty,Todd Druley,Yan Li,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William G. Blum,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark Litzow,Tara Lin,Prapti Patel,Matthew C. Foster,Michael Boyiadzis,Robert H. Collins,Jordan Chervin,Abigail Shoben,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Timothy L. Chen,Ashley O. Yocum,Franchesca Druggan,Sonja Marcus,Mona Stefanos,Brian J. Druker,Alice S. Mims,Uma Borate,Amy Burd,John C. Byrd,Ross L. Levine,Eytan M. Stein
View Articletitled, A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed <em>IDH2</em>-mutant AML
Supplemental data
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy
Clinical Trials & Observations
Kai Yu,Natalie Deuitch,Matthew Merguerian,Lea Cunningham,Joie Davis,Erica Bresciani,Jamie Diemer,Elizabeth Andrews,Alice Young,Frank Donovan,Raman Sood,Kathleen Craft,Shawn Chong,Settara Chandrasekharappa,Jim Mullikin,Paul P. Liu
View Articletitled, Genomic landscape of patients with germline <em>RUNX1</em> variants and familial platelet disorder with myeloid malignancy
Supplemental data

GENE THERAPY

Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma
Jee H. Choe,Tianzhou Yu,Jeremy S. Abramson,Mohamed Abou-el-Enein
View Articletitled, Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma
Supplemental data

HEALTH SERVICES AND OUTCOMES

Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
Clinical Trials & Observations
Hervé Ghesquières,Fanny Cherblanc,Aurélien Belot,Sophie Micon,Krimo K. Bouabdallah,Cyril Esnault,Luc-Matthieu Fornecker,Katia Thokagevistk,Maxime Bonjour,Fontanet Bijou,Corinne Haioun,Nadine Morineau,Loïc Ysebaert,Gandhi Damaj,Benoit Tessoulin,Stéphanie Guidez,Franck Morschhauser,Catherine Thiéblemont,Adrien Chauchet,Rémy Gressin,Fabrice Jardin,Christophe Fruchart,Gaëlle Labouré,Ludovic Fouillet,Pauline Lionne-Huyghe,Antoine Bonnet,Laure Lebras,Sandy Amorim,Cécile Leyronnas,Gaelle Olivier,Romain Guieze,Roch Houot,Vincent Launay,Bernard Drénou,Olivier Fitoussi,Laurence Detourmignies,Julie Abraham,Carole Soussain,Florence Lachenal,Gian Matteo Pica,Patrick Fogarty,Pascale Cony-Makhoul,Adeline Bernier,Sandra Le Guyader-Peyrou,Alain Monnereau,Frédéric Boissard,Cédric Rossi,Vincent Camus
View Articletitled, Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior
Siao-Yi Wang,Gina M. Scurti,Annika V. Dalheim,Suzanne Quinn,Patrick J. Stiff,Michael I. Nishimura
View Articletitled, Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior
Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Alexandre V. Hirayama,Erik L. Kimble,Jocelyn H. Wright,Salvatore Fiorenza,Jordan Gauthier,Jenna M. Voutsinas,Qian Wu,Cecilia C. S. Yeung,Nicolas Gazeau,Barbara S. Pender,Delaney R. Kirchmeier,Aiko Torkelson,Abigail N. Chutnik,Ryan D. Cassaday,Aude G. Chapuis,Damian J. Green,Hans-Peter Kiem,Filippo Milano,Mazyar Shadman,Brian G. Till,Stanley R. Riddell,David G. Maloney,Cameron J. Turtle
View Articletitled, Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
Supplemental data
Checkpoints: roadblocks or repairs for the CAR-T journey?
Clinical Trials & Observations
Jennifer L. Crombie,Caron A. Jacobson
View Articletitled, Checkpoints: roadblocks or repairs for the CAR-T journey?
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
Lingling Wang,Vincent Leach,Natarajan Muthusamy,John Byrd,Meixiao Long
View Articletitled, A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
Supplemental data
An immunocompetent model to uncover the secrets of bispecifics
Joseph E. Maakaron
View Articletitled, An immunocompetent model to uncover the secrets of bispecifics

LYMPHOID NEOPLASIA

Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia
Tasha L. Lin,Amit K. Jaiswal,Alexander J. Ritter,Jenna Reppas,Tiffany M. Tran,Zachary T. Neeb,Sol Katzman,Michelle L. Thaxton,Amanda Cohen,Jeremy R. Sanford,Dinesh S. Rao
View Articletitled, Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia
Supplemental data
Pharmacological profiling of a berbamine derivative for lymphoma treatment
Senlin Xu,Shunquan Wu,Mingfeng Zhang,Jun Xie,Min Lin,Lihua Jin,Jiawei Zhang,Yangmeng Wang,Mingjie Fan,Zhipeng Fang,Weini Li,Ching Ouyang,David Kwon,Natalie Que,Zhirou Li,Jinge Mao,Haonan Chen,Josephine Harris,Xiwei Wu,Jun Wu,Hongwei Yin,Wing C. Chan,David Horne,Wendong Huang
View Articletitled, Pharmacological profiling of a berbamine derivative for lymphoma treatment
Supplemental data
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia
Clinical Trials & Observations
Brian T. Hill,Shuo Ma,Clive S. Zent,Andrea M. Baran,Danielle S. Wallace,Anjali Advani,Allison Winter,Jane Winter,Leo Gordan,Reem Karmali,Jane L. Liesveld,Deborah A. Mulford,Chris Rowland,Andrew Bui,Peter Sportelli,Hari P. Miskin,Michael S. Weiss,Jonathan W. Friedberg,Paul M. Barr
View Articletitled, Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia

MYELOID NEOPLASIA

Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
Clinical Trials & Observations
Carlos Jimenez-Chillon,Jad Othman,David Taussig,Carlos Jimenez-Vicente,Alexandra Martinez-Roca,Ing Soo Tiong,Manish Jain,James Aries,Seda Cakmak,Steven Knapper,Daniel Tuyet Kristensen,Vidhya Murthy,Joy Zacharoula Galani,Charlotte Kallmeyer,Loretta Ngu,David Veale,Simon Bolam,Nina Orfali,Anne Parker,Cara Manson,Jane Parker,Thomas Erblich,Deborah Richardson,Katya Mokretar,Nicola Potter,Ulrik Malthe Overgaard,Anne Stidsholt Roug,Andrew H. Wei,Jordi Esteve,Martin Jädersten,Nigel Russell,Richard Dillon
View Articletitled, Venetoclax–based low intensity therapy in molecular failure of <em>NPM1</em>-mutated AML
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease
Clinical Trials & Observations
Minke A. E. Rab,Celeste K. Kanne,Camille Boisson,Jennifer Bos,Brigitte A. van Oirschot,Maite E. Houwing,Céline Renoux,Marije Bartels,Anita W. Rijneveld,Erfan Nur,Marjon H. Cnossen,Philippe Joly,Elie Nader,Romain Fort,Philippe Connes,Richard van Wijk,Vivien A. Sheehan,Eduard J. van Beers
View Articletitled, Oxygen gradient ektacytometry–derived biomarkers are associated with acute complications in sickle cell disease
Supplemental data

THROMBOSIS AND HEMOSTASIS

CT-001, a novel fast-clearing factor VIIa, enhanced the hemostatic activity in postpartum samples
Clinical Trials & Observations
Derek S. Sim,Cornell R. Mallari,Terry W. Hermiston,Daekyeong Bae,Sul Lee,Terrence Allen,Jennifer Gilner,Seung-Chul Kim,Andra H. James
View Articletitled, CT-001, a novel fast-clearing factor VIIa, enhanced the hemostatic activity in postpartum samples
Supplemental data
Protein S antibody as an adjunct therapy for hemophilia B
Hope P. Wilson,Aliyah Pierre,Ashley L. Paysse,Narender Kumar,Brian C. Cooley,Pratyadipta Rudra,Adrianne W. Dorsey,Diana Polania-Villanueva,Sabyasachi Chatterjee,Maissaa Janbain,Maria C. Velez,Rinku Majumder
View Articletitled, Protein S antibody as an adjunct therapy for hemophilia B
Supplemental data

RESEARCH LETTERS

Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ
Elena E. Solomou,Antonis Kattamis,Argyris Symeonidis,Chaido Sirinian,Christina Salamaliki,Marianna Tzanoudaki,Panagiotis Diamantopoulos,Eva Plakoula,Maria Palasopoulou,Nikolaos Giannakoulas,Christina-Nefeli Kontandreopoulou,Panagoula Kollia,Nora-Athina Viniou,Athanasios Galanopoulos,Stamatis-Nick Liossis,George Vassilopoulos
View Articletitled, Increased age-associated B cells in patients with acquired aplastic anemia correlate with IFN-γ
Supplemental data
Gender disparities in allograft access due to HLA-sensitization in multiparous women
Warren B. Fingrut,Eric Davis,Anne Archer,Samantha Brown,Sean Devlin,Stephanie Chinapen,Andromachi Scaradavou,Ioannis Politikos,Amanda G. Blouin,Brian C. Shaffer,Juliet N. Barker
View Articletitled, Gender disparities in allograft access due to HLA-sensitization in multiparous women

COMMENTARY

Natural history of albuminuria in a large cohort of children and adolescents with sickle cell anemia from Brazil
André Rolim Belisário,Jéssica de Almeida Costa,Ana Cristina Simões e Silva
View Articletitled, Natural history of albuminuria in a large cohort of children and adolescents with sickle cell anemia from Brazil
Supplemental data

ERRATUM

Myers G, Wang Y, Wang Q, et al. Murine erythroid differentiation kinetics in vivo under normal and anemic stress conditions. Blood Adv. 2023;7(19):5727-5732.
View Articletitled, Myers G, Wang Y, Wang Q, et al. Murine erythroid differentiation kinetics in vivo under normal and anemic stress conditions. <em>Blood Adv.</em> 2023;7(19):5727-5732.
  • Cover Image

    Cover Image

    issue cover

    Bone marrow biopsy stained with hematoxylin and eosin showing the presence of multiple myeloma. ID 303021207 © Rafael Fores | Dreamstime.com

All Issues

Advertisement intended for health care professionals

Time to revisit reduced-dose radiotherapy for PCNSL?
Lin A, Brown S, Chinapen S, et al. Patterns of CMV infection after letermovir withdrawal in recipients of posttransplant cyclophosphamide–based transplant. Blood Adv. 2023;7(23):7153-7160.
Jalink M, Jacobs CF, Khwaja J, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622-2634.
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Retreatment of multiple myeloma with previously refractory drugs

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals